Common header menu

Breadcrumb

This website contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, or in different dosages. Nothing contained herein should be considered a solicitation, promotion or advertisement for any drug including the ones under development on this web site.

Any information on the products contained herein is not intended to provide medical advice nor should be used as a substitute for the advice provided by your physician or other healthcare provider.

I Agree

Thank you for visiting the Astellas Pharma Inc. Website.
You will enter external sites beyond here.(This link opens in a new window)

The new Repatha SC Injection 420 mg AMD is a single-use on-body infusor with prefilled cartridge for every-four-week subcutaneous injection. An every-two-week subcutaneous injection option is possible for homozygous familial hypercholesterolemia (FH) patients who are unable to appropriately control their LDL cholesterol level.

Dr. Koutaro Yokote M.D., Ph.D, Professor of Chiba University Graduate School of Medicine, Department of Diabetes, Metabolism and Endocrinology and Deputy Director of Chiba University Hospital said, “There are not a few patients who are optimally treated with the exisiting therapies such as HMG-CoA reductase inhibitors (statins) and still at high risk for cardiac event. Repatha is an important treatment option for such patients.”

Amgen Astellas and Astellas expect to further contribute to the treatment of patients with FH or hypercholesterolemia patients who have high risk in cardiovascular events and do not adequately respond to statins by providing this new AMD option to the already approved Repath SC Injection 140mg Syringe and Repath SC Injection 140mg pen.